Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Sep-30-12 | Sep-30-11 | Sep-30-10 | Sep-30-09 | Sep-30-08 | Sep-30-07 | Sep-30-06 | Sep-30-05 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Instruments and Disposables | | 2.4 | 4,156.0 | 2.2 | | | | |
| Cell Culture Services | | 1.3 | 1,196.0 | 1.5 | | | | |
| Therapeutic Vaccine | 0.1 | 0.2 | | | | | | |
| Instrumentation Segment | 3.8 | | | | | | | |
| Total revenues [+] | 3.9 | 3.9 | 5.4 | 3.7 | 5.3 | 5.0 | 7.3 | 5.1 |
| Products | 3.0 | 2.4 | 4.2 | | | | | |
| Services | 0.8 | 1.3 | 1.2 | | | | | |
| Revenue growth [+] | 0.1% | -27.5% | 46.4% | -30.7% | 5.4% | -31.4% | 43.7% | |
| Instruments and Disposables | | -99.9% | 190980.5% | | | | | |
| Cell Culture Services | | -99.9% | 80656.2% | | | | | |
| Therapeutic Vaccine | -59.0% | | | | | | | |
| Cost of goods sold [+] | 2.8 | 2.5 | 2.9 | 2.5 | 3.0 | 2.7 | 3.9 | 3.8 |
| Cost of product sales | 1.9 | 1.5 | 2.0 | | | | | |
| Cost of services | 0.9 | 1.0 | 0.9 | | | | | |
| Gross profit | 1.1 | 1.4 | 2.5 | 1.2 | 2.3 | 2.3 | 3.4 | 1.3 |
| Gross margin | 28.7% | 35.8% | 45.8% | 32.9% | 43.8% | 45.3% | 46.7% | 26.1% |
| Selling, general and administrative [+] | 4.8 | 10.2 | 2.4 | 2.5 | 5.6 | 4.1 | 3.4 | 2.4 |
| General and administrative | 4.8 | 10.2 | 2.4 | 2.9 | 5.6 | 4.1 | 3.4 | 2.4 |
| Other selling, general and administrative | | | | -0.4 | | | | |
| Research and development | 4.1 | 1.8 | 0.8 | 1.1 | 3.5 | 10.2 | 12.0 | 10.0 |
| Other operating expenses | | | | 0.4 | | 10.4 | | |
| EBITDA [+] | -7.6 | -10.5 | -0.7 | -2.6 | -6.2 | -22.0 | -11.6 | -10.5 |
| EBITDA growth | -27.1% | 1485.8% | -74.6% | -58.2% | -71.7% | 90.2% | 10.0% | |
| EBITDA margin | -196.5% | -270.1% | -12.4% | -71.2% | -118.1% | -440.1% | -158.6% | -207.4% |
| Depreciation | 0.1 | 0.1 | 0.1 | 0.1 | 0.5 | 0.4 | 0.4 | 0.4 |
| EBITA | -7.8 | -10.6 | -0.7 | -2.7 | -6.8 | -22.5 | -12.0 | -11.0 |
| EBITA margin | -200.0% | -271.9% | -13.3% | -75.2% | -128.4% | -449.0% | -164.3% | -215.8% |
| Amortization of intangibles | 0.0 | 0.0 | 0.0 | 0.0 | | | 0.0 | 0.1 |
| EBIT [+] | -7.8 | -10.6 | -0.7 | -2.8 | -6.8 | -22.5 | -12.0 | -11.1 |
| EBIT growth | -26.3% | 1324.4% | -73.2% | -59.1% | -69.9% | 87.0% | 8.6% | |
| EBIT margin | -200.8% | -272.7% | -13.9% | -75.8% | -128.4% | -449.0% | -164.6% | -217.9% |
| Interest expense | 5.3 | 4.7 | 7.2 | 6.9 | 7.9 | 4.8 | | |
| Interest expense | 5.3 | 4.7 | 7.2 | 6.9 | 7.9 | 4.8 | | |
| Other income (expense), net [+] | 1.3 | 0.0 | -2.3 | -5.0 | -6.0 | -17.1 | | |
| Reorganization items | 0.2 | 0.3 | 1.6 | | | | | |
| Other | 0.0 | 0.0 | 0.3 | | | | | |
| Pre-tax income | -11.8 | -15.3 | -10.2 | -14.7 | -20.6 | -44.3 | -13.7 | -11.5 |
| Income taxes | 0.0 | 0.0 | -2.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 19.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Minority interest | | | 0.4 | | | | | |
| Net income | -11.8 | -15.3 | -9.0 | -14.7 | -20.6 | -44.3 | 0.0 | 0.0 |
| Net margin | -302.4% | -393.8% | -168.1% | -400.8% | -391.3% | -886.0% | -0.2% | -0.2% |
| |
| Basic EPS [+] | ($0.08) | ($0.11) | ($0.09) | ($0.15) | $0.00 | $0.00 | $0.00 | |
| Growth | -27.9% | 21.8% | -38.6% | | | -100.0% | | |
| Diluted EPS [+] | ($0.08) | ($0.11) | ($0.09) | ($0.15) | $0.00 | $0.00 | $0.00 | |
| Growth | -27.9% | 21.8% | -38.6% | | | -100.0% | | |
| |
| Shares outstanding (basic) [+] | 145.2 | 136.1 | 97.6 | 97.5 | 95.8 | 94.5 | 73.4 | |
| Growth | 6.7% | 39.5% | 0.1% | 1.8% | 1.4% | 28.8% | | |
| Shares outstanding (diluted) [+] | 145.2 | 136.1 | 97.6 | 97.5 | 95.8 | 94.5 | 73.4 | |
| Growth | 6.7% | 39.5% | 0.1% | 1.8% | 1.4% | 28.8% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|